Alnylam Pharmaceuticals | ALNY - 营业费用



金融业
股票价格
USD
资产
USD 5.56B
现金及等价物
USD 1.71B
销售成本
USD 298.45M
流动资产
USD 4.62B
流动负债
USD 1.51B
债务
USD 1.27B
EBIT
USD 112.6M
EBITDA
USD 245.34M
员工
2.23K
EPS每股收益
USD 1.84
股本和储备
USD 1.35B
销售毛利
USD 992.69M
债务利息支出
USD 82.05M
利息收入
USD 26.6M
贷款资金
USD 2.47B
市值
USD 31.33B
净收入
USD 164.49M
营业费用
USD 1.06B
营业利润
USD 112.6M
普通股股本
USD 133.73M
PE价格收益
75.64
税前利润
USD 177.81M
销售收入
USD 1.29B
销售和管理费用
USD 347.92M
股票
USD 97.11M
贸易债权人
USD 108.02M
应收帐款人
USD 912.74M


营业费用 更改 日
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Amgen USD 11.69B 6.9B 2026-06
Arrowhead Research USD 245.35M 30.35M 2026-06
BioCryst Pharmaceuticals USD 119.78M 673.63M 2026-06
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
Incyte USD 973.64M 4.65B 2026-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Moderna USD 960M 817M 2026-06
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Novartis USD 9.29B 507M 2026-03
PTC Therapeutics USD 226.66M 19.64M 2026-03
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 8.98B 1.73B 2026-03
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Takeda JPY 1.02T 89.68B 2026-06
Tectonic Therapeutic USD 27.3M 5.78M 2026-03
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
Vertex Pharmaceuticals USD 2.07B 217.1M 2026-06
Xencor USD 87.82M 5.44M 2026-06